EP3442983A1 — TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
Assigned to F Hoffmann La Roche AG · Expires 2019-02-20 · 7y expired
What this patent protects
This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N- Acetylgalactosamine (GalNAc) compounds, in particular phosphoramidite or phosphonoamidite molecules of formula (I) with only one GalNAc moiety (formula II) and…
USPTO Abstract
This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N- Acetylgalactosamine (GalNAc) compounds, in particular phosphoramidite or phosphonoamidite molecules of formula (I) with only one GalNAc moiety (formula II) and to conjugates of nucleic acid molecules with such N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine. Wherein R 1 is H or C 1 - 6 alkyl; R 2 is a triphenylmethyl-based hydroxyl protecting group R 3 is a phosphorus-containing group, particularly a phosphoramidite or a phosphonoamidite group, and K is represented by the general formula (II).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.